الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

santa fe distillery, llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - mibelas™ 24 fe is indicated for use by females of reproductive age to prevent pregnancy [see clinical studies (14)]. the efficacy of mibelas 24 fe in women with a body mass index (bmi) of more than 35 kg/m2 has not been evaluated. mibelas 24 fe is contraindicated in females who are known to have or develop the following conditions: • a high risk of arterial or venous thrombotic diseases. examples include women who are known to: • smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]   • have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)]   • have cerebrovascular disease [see warnings and precautions (5.1)] • have coronary artery disease [see warnings and precautions (5.1)] • have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] • have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] • have uncontrolled hypertension [see warnings and precautions (5.3)]   • have diabetes mellitus with vascular disease [see warnings and precautions (5.5)]   • have headaches with focal neurological symptoms or have migraine headaches with aura o    all women over age 35 with migraine headache [see warnings and precautions (5.6)] • liver tumors, benign or malignant, or liver disease [see warnings and precautions (5.2)] • undiagnosed abnormal uterine bleeding [see warnings and precautions (5.7)] • pregnancy, because there is no reason to use cocs during pregnancy [see warnings and precautions (5.8) and use in specific populations (8.1)] • current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see warnings and precautions (5.10)] • use of hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations [see warnings and precautions (5.3)] there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce withdrawal bleeding should not be used as a test for pregnancy. cocs should not be used during pregnancy to treat threatened or habitual abortion. when possible, advise the nursing mother to use other forms of contraception until she has weaned her child. cocs can reduce milk production in breastfeeding mothers. this is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. small amounts of oral contraceptive steroids and/or metabolites are present in breast milk safety and efficacy of mibelas 24 fe have been established in women of reproductive age. efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. use of this product before menarche is not indicated. mibelas 24 fe has not been studied in postmenopausal women and is not indicated in this population. the pharmacokinetics of mibelas 24 fe has not been studied in subjects with renal impairment. the pharmacokinetics of mibelas 24 fe has not been studied in subjects with hepatic impairment. however, steroid hormones may be poorly metabolized in patients with hepatic impairment. acute or chronic disturbances of liver function may necessitate the discontinuation of coc use until markers of liver function return to normal and coc causation has been excluded [see contraindications (4) and warnings and precautions (5.2)]. the safety and efficacy of mibelas 24 fe in women with a body mass index (bmi) greater than 35 kg/m2 has not been evaluated [see clinical studies (14)].

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

slv pharmaceuticals llc dba aum pharmaceuticals - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - neonatal fe rx prenatal vitamin with ferronyl iron vitamin is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: ● thrombophlebitis or thromboembolic disorders ● a past history of deep vein thrombophlebitis or thromboembolic disorders ● cerebral vascular or coronary artery disease ● known or suspected carcinoma of the breast ● carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia ● undiagnosed abnormal genital bleeding ● cholestatic jaundice of pregnancy or jaundice with prior pill use ● hepatic

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: ● thrombophlebitis or thromboembolic disorders ● a past history of deep vein thrombophlebitis or thromboembolic disorders ● cerebral vascular or coronary artery disease ● known or suspected carcinoma of the breast ● carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia ● undiagnosed abnormal genital bleeding ● cholestatic jaundice of pregnancy or jaundice with prior pill use ● hepat

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin 24 fe is indicated for use by women to prevent pregnancy [see clinical studies (14)] . the efficacy of microgestin 24 fe in women with a body mass index (bmi) of > 35 kg/m2 has not been evaluated. do not prescribe microgestin 24 fe to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35[ see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past[see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies[see warnings and precautions (5.1)] have cerebrovascular disease[see warnings and precautions (5.1)] have coronary artery disease[see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)[see warnings and precautions (5.1)] have uncontrolle

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - wymzyatm fe is indicated for use by females of reproductive potential to prevent pregnancy. wymzya fe is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have uncontrolled hypertension [see warnings and precautions (5.4)] have diabetes mellitus with vascular disease [see warnings and precautions (5.6)] have headaches with focal neurological symptoms or have migraine headaches with aura [see warnings and precautions (5.7)] - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] - have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] - have cerebrovascular disease [see warnings and precautions (5.1)] - have coronary artery disease [see warnings and precautions (5.1)] - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] - have uncontrolled hypertension [see warnings and precautions (5.4)] - have diabetes mellitus with vascular disease [see warnings and precautions (5.6)] - have headaches with focal neurological symptoms or have migraine headaches with aura [see warnings and precautions (5.7)] there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. do not use cocs to induce withdrawal bleeding as a test for pregnancy. do not use cocs during pregnancy to treat threatened or habitual abortion. advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. cocs can reduce milk production in breastfeeding mothers. this is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. small amounts of oral contraceptive steroids and/or metabolites are present in breast milk. safety and efficacy of wymzya fe have been established in women of reproductive age. efficacy is expected to be the same in post-pubertal adolescents under the age of 18 years as for users 18 years and older. use of this product before menarche is not indicated. wymzya fe has not been studied in postmenopausal women and is not indicated in this population. the pharmacokinetics of wymzya fe has not been studied in women with hepatic impairment. however, steroid hormones may be poorly metabolized in patients with hepatic impairment. acute or chronic disturbances of liver function may necessitate the discontinuation of coc use until markers of liver function return to normal and coc causation has been excluded [see contraindications (4) and warnings and precautions (5.2)]. the pharmacokinetics of wymzya fe has not been studied in women with renal impairment.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

puretek corporation - chromium nicotinate (unii: a150ay412v) (chromic cation - unii:x1n4508kf1), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), vitamin a acetate (unii: 3le3d9d6oy) (vitamin a - unii:81g40h8b0t), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium carbonate (unii: h0g - vitrexate fe is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age.also for the treatment of a condition in which iron deficiency and vitamin c deficiency occur together, along with a deficient intake or increased need for b-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. this product is contraindicated in patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - tilia fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. tilia fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. tilia fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. oral contraceptives are highly effective for pregnancy prevention. table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table 2. percentage of women experiencing an unintended pregnanc

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) -  tarina 24 fe is indicated for use by women to prevent pregnancy [see clinical studies (14)] . the efficacy of tarina 24 fe in women with a body mass index (bmi) of greater than 35 kg/m2 has not been evaluated. tarina 24 fe is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions